Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

XRAY vs DBVT vs ALGN vs ALKS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
XRAY
DENTSPLY SIRONA Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$2.20B
5Y Perf.-76.4%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-58.8%
ALGN
Align Technology, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$12.06B
5Y Perf.-31.4%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+116.4%

XRAY vs DBVT vs ALGN vs ALKS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
XRAY logoXRAY
DBVT logoDBVT
ALGN logoALGN
ALKS logoALKS
IndustryMedical - Instruments & SuppliesBiotechnologyMedical - DevicesBiotechnology
Market Cap$2.20B$1712.35T$12.06B$5.90B
Revenue (TTM)$3.68B$0.00$4.10B$1.56B
Net Income (TTM)$-628M$-168M$430M$153M
Gross Margin48.9%67.7%65.4%
Operating Margin4.1%14.4%12.3%
Forward P/E7.7x14.9x24.8x
Total Debt$2.47B$22M$114M$70M
Cash & Equiv.$326M$194M$1.08B$1.12B

XRAY vs DBVT vs ALGN vs ALKSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

XRAY
DBVT
ALGN
ALKS
StockMay 20May 26Return
DENTSPLY SIRONA Inc. (XRAY)10023.6-76.4%
DBV Technologies S.… (DBVT)10041.2-58.8%
Align Technology, I… (ALGN)10068.6-31.4%
Alkermes plc (ALKS)100216.4+116.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: XRAY vs DBVT vs ALGN vs ALKS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALGN leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DENTSPLY SIRONA Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. DBVT and ALKS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
XRAY
DENTSPLY SIRONA Inc.
The Value Play

XRAY is the #2 pick in this set and the best alternative if value and dividends is your priority.

  • Lower P/E (7.7x vs 14.9x)
  • 5.9% yield; 23-year raise streak; the other 3 pay no meaningful dividend
Best for: value and dividends
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +110.4% vs XRAY's -16.4%
Best for: income & stability
ALGN
Align Technology, Inc.
The Growth Play

ALGN carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 0.9%, EPS growth 0.5%, 3Y rev CAGR 2.6%
  • 0.9% revenue growth vs DBVT's -100.0%
  • 10.5% margin vs XRAY's -17.1%
  • 6.9% ROA vs DBVT's -89.0%
Best for: growth exposure
ALKS
Alkermes plc
The Long-Run Compounder

ALKS is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • -11.0% 10Y total return vs ALGN's 122.8%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • Beta 1.06 vs XRAY's 1.78, lower leverage
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthALGN logoALGN0.9% revenue growth vs DBVT's -100.0%
ValueXRAY logoXRAYLower P/E (7.7x vs 14.9x)
Quality / MarginsALGN logoALGN10.5% margin vs XRAY's -17.1%
Stability / SafetyALKS logoALKSBeta 1.06 vs XRAY's 1.78, lower leverage
DividendsXRAY logoXRAY5.9% yield; 23-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs XRAY's -16.4%
Efficiency (ROA)ALGN logoALGN6.9% ROA vs DBVT's -89.0%

XRAY vs DBVT vs ALGN vs ALKS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

XRAYDENTSPLY SIRONA Inc.
FY 2022
Technologies And Equipment
59.1%$2.3B
Consumables Segment
40.9%$1.6B
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALGNAlign Technology, Inc.
FY 2025
Clear Aligner
80.4%$3.2B
Scanners And Services
19.6%$790M
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M

XRAY vs DBVT vs ALGN vs ALKS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLXRAYLAGGINGALKS

Income & Cash Flow (Last 12 Months)

ALGN leads this category, winning 3 of 6 comparable metrics.

ALGN and DBVT operate at a comparable scale, with $4.1B and $0 in trailing revenue. ALGN is the more profitable business, keeping 10.5% of every revenue dollar as net income compared to XRAY's -17.1%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricXRAY logoXRAYDENTSPLY SIRONA I…DBVT logoDBVTDBV Technologies …ALGN logoALGNAlign Technology,…ALKS logoALKSAlkermes plc
RevenueTrailing 12 months$3.7B$0$4.1B$1.6B
EBITDAEarnings before interest/tax$424M-$112M$790M$212M
Net IncomeAfter-tax profit-$628M-$168M$430M$153M
Free Cash FlowCash after capex$104M-$151M$717M$392M
Gross MarginGross profit ÷ Revenue+48.9%+67.7%+65.4%
Operating MarginEBIT ÷ Revenue+4.1%+14.4%+12.3%
Net MarginNet income ÷ Revenue-17.1%+10.5%+9.8%
FCF MarginFCF ÷ Revenue+2.8%+17.5%+25.1%
Rev. Growth (YoY)Latest quarter vs prior year+0.1%+6.2%+28.2%
EPS Growth (YoY)Latest quarter vs prior year-150.0%+91.5%+23.6%-4.1%
ALGN leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

XRAY leads this category, winning 4 of 6 comparable metrics.

At 24.8x trailing earnings, ALKS trades at a 17% valuation discount to ALGN's 29.8x P/E. On an enterprise value basis, XRAY's 7.2x EV/EBITDA is more attractive than ALKS's 17.3x.

MetricXRAY logoXRAYDENTSPLY SIRONA I…DBVT logoDBVTDBV Technologies …ALGN logoALGNAlign Technology,…ALKS logoALKSAlkermes plc
Market CapShares × price$2.2B$1712.35T$12.1B$5.9B
Enterprise ValueMkt cap + debt − cash$4.3B$1712.35T$11.1B$4.9B
Trailing P/EPrice ÷ TTM EPS-3.65x-0.76x29.80x24.76x
Forward P/EPrice ÷ next-FY EPS est.7.68x14.85x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.18x13.92x17.25x
Price / SalesMarket cap ÷ Revenue0.60x2.99x4.00x
Price / BookPrice ÷ Book value/share1.63x0.66x3.02x3.28x
Price / FCFMarket cap ÷ FCF21.11x24.57x12.28x
XRAY leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

ALGN leads this category, winning 6 of 9 comparable metrics.

ALGN delivers a 10.7% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-130 for DBVT. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), ALGN scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricXRAY logoXRAYDENTSPLY SIRONA I…DBVT logoDBVTDBV Technologies …ALGN logoALGNAlign Technology,…ALKS logoALKSAlkermes plc
ROE (TTM)Return on equity-41.2%-130.2%+10.7%+8.8%
ROA (TTM)Return on assets-11.2%-89.0%+6.9%+5.4%
ROICReturn on invested capital+5.1%+15.4%+18.9%
ROCEReturn on capital employed+6.1%-145.7%+14.5%+14.2%
Piotroski ScoreFundamental quality 0–96477
Debt / EquityFinancial leverage1.84x0.13x0.03x0.04x
Net DebtTotal debt minus cash$2.1B-$172M-$965M-$1.0B
Cash & Equiv.Liquid assets$326M$194M$1.1B$1.1B
Total DebtShort + long-term debt$2.5B$22M$114M$70M
Interest CoverageEBIT ÷ Interest expense-5.12x-189.82x389.13x32.30x
ALGN leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $1,991 for XRAY. Over the past 12 months, DBVT leads with a +110.4% total return vs XRAY's -16.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs XRAY's -32.6% — a key indicator of consistent wealth creation.

MetricXRAY logoXRAYDENTSPLY SIRONA I…DBVT logoDBVTDBV Technologies …ALGN logoALGNAlign Technology,…ALKS logoALKSAlkermes plc
YTD ReturnYear-to-date-2.8%+4.9%+7.9%+25.3%
1-Year ReturnPast 12 months-16.4%+110.4%-2.2%+16.5%
3-Year ReturnCumulative with dividends-69.4%+19.7%-45.0%+14.5%
5-Year ReturnCumulative with dividends-80.1%-69.1%-71.9%+60.9%
10-Year ReturnCumulative with dividends-74.5%-87.0%+122.8%-11.0%
CAGR (3Y)Annualised 3-year return-32.6%+6.2%-18.1%+4.6%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs XRAY's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricXRAY logoXRAYDENTSPLY SIRONA I…DBVT logoDBVTDBV Technologies …ALGN logoALGNAlign Technology,…ALKS logoALKSAlkermes plc
Beta (5Y)Sensitivity to S&P 5001.78x1.26x1.66x1.06x
52-Week HighHighest price in past year$17.18$26.18$208.31$36.60
52-Week LowLowest price in past year$9.85$7.53$122.00$25.17
% of 52W HighCurrent price vs 52-week peak+63.8%+76.3%+80.8%+96.7%
RSI (14)Momentum oscillator 0–10039.248.144.660.2
Avg Volume (50D)Average daily shares traded4.2M252K1.1M2.3M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

XRAY leads this category, winning 1 of 1 comparable metric.

Analyst consensus: XRAY as "Hold", DBVT as "Buy", ALGN as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 20.9% for ALGN (target: $204). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.

MetricXRAY logoXRAYDENTSPLY SIRONA I…DBVT logoDBVTDBV Technologies …ALGN logoALGNAlign Technology,…ALKS logoALKSAlkermes plc
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuy
Price TargetConsensus 12-month target$13.40$46.33$203.60$44.00
# AnalystsCovering analysts31153328
Dividend YieldAnnual dividend ÷ price+5.9%
Dividend StreakConsecutive years of raises2300
Dividend / ShareAnnual DPS$0.64
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.9%+0.5%
XRAY leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ALGN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 2 (Valuation Metrics, Analyst Outlook).

Best OverallDENTSPLY SIRONA Inc. (XRAY)Leads 2 of 6 categories
Loading custom metrics...

XRAY vs DBVT vs ALGN vs ALKS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is XRAY or DBVT or ALGN or ALKS a better buy right now?

For growth investors, Align Technology, Inc.

(ALGN) is the stronger pick with 0. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — XRAY or DBVT or ALGN or ALKS?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Align Technology, Inc. at 29. 8x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — XRAY or DBVT or ALGN or ALKS?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -80. 1% for DENTSPLY SIRONA Inc. (XRAY). Over 10 years, the gap is even starker: ALGN returned +122. 8% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — XRAY or DBVT or ALGN or ALKS?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 68% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — XRAY or DBVT or ALGN or ALKS?

By revenue growth (latest reported year), Align Technology, Inc.

(ALGN) is pulling ahead at 0. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: DENTSPLY SIRONA Inc. grew EPS 33. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — XRAY or DBVT or ALGN or ALKS?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -16. 3% for DENTSPLY SIRONA Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is XRAY or DBVT or ALGN or ALKS more undervalued right now?

On forward earnings alone, DENTSPLY SIRONA Inc.

(XRAY) trades at 7. 7x forward P/E versus 14. 9x for Align Technology, Inc. — 7. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — XRAY or DBVT or ALGN or ALKS?

In this comparison, XRAY (5.

9% yield) pays a dividend. DBVT, ALGN, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is XRAY or DBVT or ALGN or ALKS better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Align Technology, Inc. (ALGN) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, ALGN: +122. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between XRAY and DBVT and ALGN and ALKS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XRAY is a small-cap income-oriented stock; DBVT is a mega-cap quality compounder stock; ALGN is a mid-cap quality compounder stock; ALKS is a small-cap quality compounder stock. XRAY pays a dividend while DBVT, ALGN, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

XRAY

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 29%
  • Dividend Yield > 2.3%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALGN

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.